Moleculin Biotech, Inc.
Developing therapies for hard-to-treat tumors (like AML) and viruses.
MBRX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US60855D2009
- LEI:
- Country:
- United States of America
- Address:
- 5300 MEMORIAL DRIVE, 77007 HOUSTON
- Website:
- https://moleculin.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company advancing a pipeline of therapeutic candidates for hard-to-treat tumors and viruses. The company's lead program, Annamycin, is being developed for the treatment of second-line acute myeloid leukemia (AML) and is preparing to commence a pivotal Phase 3 clinical trial. The development portfolio also includes other drug candidates, such as WP1066 for brain tumors and additional antimetabolites, targeting a broad range of highly resistant cancers and viral diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Moleculin Biotech, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Moleculin Biotech, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Moleculin Biotech, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
